Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Valagussa

Showing results (141-150 of 196) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year resultsS Viviani, G Bonadonna, A Santoro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Istituto Nazionale per lo Studio e las Cura dei TumoriM Greco, M Gennaro, P Valagussa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiationM Zambetti, A Moliterni, C Materazzo, et al.
Breast Cancer Research and Treatment|June 16, 1999
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'R Demicheli, R Miceli, C Brambilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancerR Silvestrini, M G Daidone, P Valagussa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Testicular dysfunction in Hodgkin's disease before and after treatmentS Viviani, G Ragni, A Santoro, et al.
Surgery, Gynecology & Obstetrics|December 1, 1975
Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovaryG M de Palo, M de Lena, F Di Re, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Combined sequential approach in locally advanced breast cancerM Zambetti, S Oriana, P Quattrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
Drugs ten years later: epirubicinG Bonadonna, L Gianni, A Santoro, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1984
A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classificationsS Monfardini, F Rilke, P Valagussa, et al.
Pageof 20

Showing results (141-150 of 196) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year resultsS Viviani, G Bonadonna, A Santoro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Istituto Nazionale per lo Studio e las Cura dei TumoriM Greco, M Gennaro, P Valagussa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiationM Zambetti, A Moliterni, C Materazzo, et al.
Breast Cancer Research and Treatment|June 16, 1999
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'R Demicheli, R Miceli, C Brambilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancerR Silvestrini, M G Daidone, P Valagussa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Testicular dysfunction in Hodgkin's disease before and after treatmentS Viviani, G Ragni, A Santoro, et al.
Surgery, Gynecology & Obstetrics|December 1, 1975
Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovaryG M de Palo, M de Lena, F Di Re, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 1999
Combined sequential approach in locally advanced breast cancerM Zambetti, S Oriana, P Quattrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1993
Drugs ten years later: epirubicinG Bonadonna, L Gianni, A Santoro, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1984
A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classificationsS Monfardini, F Rilke, P Valagussa, et al.
Pageof 20